Investment
Features
FeesSafety
Academy
More
Pluang+

Compare IDEXX Laboratories, Inc. (IDXX) vs Las Vegas Sands Corp. (LVS) Price & Performance

IDEXX Laboratories, Inc.Trade
Las Vegas Sands Corp.Trade

Price performance (Past 24H)

Key statistics

IDEXX Laboratories, Inc. vs Las Vegas Sands Corp. — how do they compare? IDEXX Laboratories, Inc. trades at $589.8 (market cap $46.22B), while Las Vegas Sands Corp. trades at $45.83 (market cap $29.44B). The key difference: IDEXX Laboratories, Inc. is the larger of the two by market cap, and Las Vegas Sands Corp. pays a 2.64% dividend while IDEXX Laboratories, Inc. pays none. Which is the better fit depends on your goals.

IDXXLVS
Market Cap
$46.22B$29.44B
Sector
HealthConsumer Cyclical
52-Week High
$766.68$69.49
52-Week Low
$526.44$44.78
Enterprise Value
$47.12B$41.33B
Dividend Yield
2.64%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

IDEXX Laboratories, Inc.

No Aura AI signal available yet.

Las Vegas Sands Corp.

LVS trades at $45.46, down 0.68% today, with a bearish technical signal from moving averages. The company reported mixed Q2 2026 earnings, missing EPS estimates at $0.59 versus $0.757 expected, but revenue growth remains robust with 2025 revenue at $13.02B. Analyst consensus is strongly bullish with a $60.75 price target and no sell ratings among 49 analysts. Recent news highlights corporate responsibility efforts and operational achievements in Macao.

The outlook is supported by strong fundamentals including a 12.59% net income margin and positive cash flow trends, but risks include high debt levels and competitive pressures. Upside potential exists if earnings rebound in Q3, aligning with analyst optimism, though technical weakness near support at $44 requires monitoring for stability.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About IDEXX Laboratories, Inc.

Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.

Read more on IDXX

About Las Vegas Sands Corp.

Las Vegas Sands is the world's largest operator of fully integrated resorts, featuring casino, hotel, entertainment, food and beverage, retail, and convention center operations. The company owns the Venetian Macao, Sands Macao, Londoner, Four Seasons Hotel Macao, and Parisian in Macao, and the Marina Bay Sands resort in Singapore. Its Venetian and Palazzo Las Vegas in the U.S. asets were sold to Apollo and VICI for $6.25 billion in 2022. We expect Sands to open a fourth tower in Singapore in 2026. After the sale of its Vegas assets, the company will generate all its EBITDA from Asia, with its casino operations generating the majority of sales.

Read more on LVS